Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody
- PMID: 9893971
- DOI: 10.1021/bc980091d
Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody
Abstract
We evaluated the in vivo biodistribution of indium- and yttrium-labeled second-generation polyamidoamine dendrimer (PAMAM) conjugated with 2-(p-isothiocyanatobenzyl)-6-methyl-diethylenetriaminepentaacetic acid (1B4M), a derivative of DTPA. In addition, we conjugated PAMAM-1B4M to humanized anti-Tac IgG (HuTac) and evaluated its in vitro and in vivo properties. PAMAM-1B4M was labeled with 111In at 37-48 MBq/mg (1.0-1.3 mCi/mg) or with 88Y at 3.7-4.8 MBq/mg (0.1-0. 13 mCi/mg), and an aliquot of radiolabeled conjugate was saturated with the corresponding stable yttrium or indium. Nontumor-bearing nude mice were injected intravenously with 55.5-66.6 kBq (1.5-1.8 microCi) of 88Y-labeled PAMAM-1B4M or with 185 kBq (5 microCi) of 111In-labeled PAMAM-1B4M. The mice were then sacrificed at 15 min, 90 min, 1 day, and 4 days postinjection. Then the PAMAM-1B4M was conjugated with HuTac and labeled with 111In at 111-259 MBq/mg (3-7 mCi/mg). Another preparation of 111In-labeled HuTac-PAMAM-1B4M was saturated with stable indium. Immunoreactivity of both preparations and biodistribution in normal mice 1 h after injection and in ATAC4 and A431 tumor-bearing mice 18 h after injection were evaluated and compared with those of 111In-labeled 1B4M-HuTac. We noted significantly higher accumulations (p < 0.05) of 111In-labeled and 88Y-labeled unsaturated PAMAM-1B4M than saturated preparations in the liver, kidney, spleen, and bone at most time points. The whole-body clearance times of unsaturated preparations were significantly slower than those of saturated preparations at all time points, with the exception of 168 h for 111In-labeled PAMAM-1B4M. The saturated preparation of 111In-labeled HuTac-PAMAM-1B4M showed lower hepatic uptake (27 +/- 2%ID/g) than the unsaturated (32 +/- 2%ID/g), but greater than the HuTac-1B4M control (10 +/- 0%ID/g). The splenic uptake showed 15 +/- 1, 38 +/- 5, and 8 +/- 1%ID/g for the saturated, unsaturated, and control, respectively. The biodistribution of the dendrimer conjugated HuTac in normal organs of tumor-bearing mice was similar to nontumor-bearing mice. Specific tumor (ATAC4) uptake was higher than that in nonspecific tumor (A431). In conclusion, we evaluated the biodistribution of radiolabeled PAMAM-1B4M. We noted high accumulation in the liver, kidney, and spleen, which significantly decreased when the chelates were saturated with the stable element. A similar phenomenon was observed between unsaturated and saturated 111In-labeled HuTac-PAMAM-1B4M, indicating that the PAMAM dendrimer had a detrimental effect on biodistribution.
Similar articles
-
Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.J Nucl Med. 1994 May;35(5):882-9. J Nucl Med. 1994. PMID: 8176477
-
Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies.J Nucl Med. 1998 May;39(5):829-36. J Nucl Med. 1998. PMID: 9591585
-
Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.J Nucl Med. 1999 Feb;40(2):268-76. J Nucl Med. 1999. PMID: 10025834
-
Preparation and use of DTPA-coupled antitumor antibodies radiolabeled with yttrium-90.Targeted Diagn Ther. 1988;1:353-74. Targeted Diagn Ther. 1988. PMID: 2979062 Review. No abstract available.
-
111In-Diethylenetriaminepentaacetic acid-2-(p-isothiocyanatobenzyl)-6-methyl-B3 monoclonal antibody.2009 Mar 17 [updated 2009 May 13]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2009 Mar 17 [updated 2009 May 13]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641590 Free Books & Documents. Review.
Cited by
-
Dendrimers in medical nanotechnology.IEEE Eng Med Biol Mag. 2009 Jan-Feb;28(1):12-22. doi: 10.1109/MEMB.2008.931012. IEEE Eng Med Biol Mag. 2009. PMID: 19150767 Free PMC article. Review.
-
Nuclear molecular imaging with nanoparticles: radiochemistry, applications and translation.Br J Radiol. 2015 Oct;88(1054):20150185. doi: 10.1259/bjr.20150185. Epub 2015 Jul 2. Br J Radiol. 2015. PMID: 26133075 Free PMC article. Review.
-
Nanosystems for simultaneous imaging and drug delivery to T cells.AAPS J. 2007 Jun 8;9(2):E171-80. doi: 10.1208/aapsj0902019. AAPS J. 2007. PMID: 17614359 Free PMC article. Review.
-
New insights into nanosystems for non-small-cell lung cancer: diagnosis and treatment.RSC Adv. 2023 Jun 28;13(28):19540-19564. doi: 10.1039/d3ra03099g. eCollection 2023 Jun 22. RSC Adv. 2023. PMID: 37388143 Free PMC article. Review.
-
Imaging and drug delivery using theranostic nanoparticles.Adv Drug Deliv Rev. 2010 Aug 30;62(11):1052-1063. doi: 10.1016/j.addr.2010.08.004. Epub 2010 Aug 13. Adv Drug Deliv Rev. 2010. PMID: 20709124 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources